SCHEMBL5960702

SCHEMBL5960702

C=CCc1oc2ccc(O)cc2c1N

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC22A12 Q96S37 2/20 0.40
EYA3 Q99504 2/20 0.40
LCK P06239 1/20 0.38
ESR2 Q92731 2/20 0.38
ESR1 P03372 1/20 0.38
CYP3A4 P08684 3/20 0.37
MAOA P21397 2/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2C19 P33261 1/20 0.37
PDE2A O00408 1/20 0.36
MAPT P10636 4/20 0.36
RAB9A P51151 3/20 0.36
LMNA P02545 2/20 0.36
ALOX15 P16050 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
NPC1 O15118 2/20 0.36
TP53 P04637 1/20 0.36
THRB P10828 1/20 0.36
HPGD P15428 1/20 0.36
CASP3 P42574 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3264173 0.77 KDM4E (0.46) MAPTRAB9ALMNAALOX15SMN1; SMN2
SCHEMBL5308204 0.67 MAPT (0.64) ESR2ESR1CYP3A4MAOACYP1A2
SCHEMBL12660566 0.66 KDM4E (0.69) LCKESR2ESR1CYP3A4MAOA
SCHEMBL12660569 0.66 KDM4E (0.51) LCKESR2ESR1CYP3A4MAOA
SCHEMBL6483512 0.65 MAPT (0.62) LCKESR2ESR1CYP3A4MAOA
SCHEMBL9296359 0.65 GABRA1 (0.47) ESR2ESR1MAPTHPGDKDM4E
SCHEMBL2141567 0.64 EYA3 (0.69) SLC22A12EYA3ESR1CYP3A4CYP1A2
SCHEMBL2503422 0.64 GABRA1 (0.46) ESR2ESR1MAPTHPGDKDM4E
SCHEMBL739294 0.61 HSD17B3 (0.68) LCKCYP1A2LMNAHPGDKDM4E
SCHEMBL23532095 0.61 SLC22A12 (0.42) SLC22A12EYA3CYP1A2CYP2C19MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7005448-B2 Aminoalkyl-benzofuran-5-ol compounds for the treatment of glaucoma ALCON, INC. (CH) 2006-02-28 US disclosed
US-20040259941-A1 Aminoalkyl-benzofuran-5-ol compounds for the treatment of glaucoma NOVARTIS AG (CH) 2004-12-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040259941-A1 Aminoalkyl-benzofuran-5-ol compounds for the treatment of glaucoma TRPC5, TRPV5, PDE5A SLC22A12 1325/4885EYA3 52/4885LCK 4202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.